Federal Supply Schedule 36F79720D0180
Award Date
9/1/20
Last Date to Order
8/31/26
Federal Agency
Veterans Integrated Service Network 12
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer of pharmaceutical goods. The BPA, valued at $21.5 million, is for the procurement of Kymriah, a specialized cell therapy cancer treatment. Kymriah is a chimeric antigen receptor T-cell (CAR-T) therapy provided by Novartis under the company's Federal Supply Schedule...
The Federal Supply Schedule (FSS) contract identified as 36F79720D0225 was awarded by the U.S. Department of Veterans Affairs (VA) to Novartis Gene Therapies Inc. on September 15, 2020. This multiple-award, indefinite delivery vehicle (IDV) contract is under the Pharmaceuticals and Drugs (FSS-61-IB) category, with a total ceiling value of $6,000,000,000 and a period of performance extending until September 14, 2026. The purpose of this contract is to provide the VA with a broad range of...
The U.S. Department of Veterans Affairs (VA) has awarded Sandoz Inc., a Novartis subsidiary, an indefinite delivery vehicle (IDV) under the Federal Supply Schedule for Pharmaceuticals and Drugs (FSS-61-IB). The contract, valued at $16.85 billion, allows the VA, Department of Defense, Bureau of Prisons, and Indian Health Services to order a variety of pharmaceutical products from Sandoz's commercial catalog, including antibiotics, chemotherapy drugs, ophthalmic solutions, psychiatric medications,...
The U.S. Department of Veterans Affairs (VA) has awarded a $98.2 million multiple-award indefinite-delivery vehicle (IDV) contract under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) to Ferring Pharmaceuticals Inc., a for-profit manufacturer of pharmaceutical goods. The contract, with a period of performance through December 2025, enables the VA to efficiently procure the oncology medication Adstiladrin (nadofaragene firadenovec) to support the provision of healthcare...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract, valued at up to $3.5 million, to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company. The contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, facilitates the procurement of TARPEYO, an innovative treatment for uncontrolled protein in urine due to primary immunoglobulin A nephropathy, a serious renal condition impacting some veterans. In addition to the FSS...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple-award Federal Supply Schedule (FSS) contract to Kyowa Kirin, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the procurement of "Drugs, Pharmaceuticals, & Hematology Related Products." This FSS contract has a potential ceiling value of $17,788,800 and a period of performance through September 29, 2027. Additionally, the VA National Acquisition Center has awarded a single-award Blanket Purchase...
The Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule (FSS) contract, V797D70240, to Helsinn Therapeutics (U.S.), Inc. (doing business as Helsinn Therapeutics US Inc.), a for-profit manufacturer of pharmaceutical products. The FSS contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, has a ceiling value of $3,281,482.80 and a period of performance through February 2025. Under this FSS contract, Helsinn Therapeutics has received several delivery order...
The U.S. Department of Veterans Affairs (VA) has awarded a single-award Blanket Purchase Agreement (BPA) to Ferring Pharmaceuticals Inc., a for-profit manufacturer of pharmaceutical goods, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The $5.96 million BPA, with a period of performance through March 2026, enables the VA to procure the drug Adstiladrin (nadofaragene firadenovec), a treatment for genitourinary cancers, to support the provision of healthcare services to...
The key details of this federal contract IDV award are as follows: The Department of Veterans Affairs (VA) awarded a $3.5 billion Federal Supply Schedule (FSS) contract to Astellas Pharma US, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the provision of drugs, pharmaceuticals, and hematology-related products. The contract was awarded by the VA's Veterans Integrated Service Network 12 (VISN 12) and has an ultimate completion date of September 29, 2026. Under this FSS...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple award Federal Supply Schedule (FSS-61-IB) contract to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, with a ceiling value of $78 million through July 2025. This contract enables the VA to procure pharmaceuticals and drug products, such as TEGSEDI and ORFADIN, to support healthcare services for veterans. Additionally, the VA National Acquisition Center has awarded a single-award Blanket Purchase Agreement (BPA)...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Last Date To Order (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
36F79720D0180-36E79720A0019 | Novartis Pharmaceuticals Corporation | $21.5m | 9/30/20 | 9/29/25 | 6/3/25 |
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Delivery Order 36F79720D0180-36C24921N0300 | Novartis Pharmaceuticals Corporation | $283.6k | 1/12/21 | 1/21/21 | 1/12/21 | |
Delivery Order 36F79720D0180-36C25725N0376 | Novartis Pharmaceuticals Corporation | $1.1m | 7/1/25 | 6/30/26 | 6/16/25 | |
Delivery Order 36F79720D0180-36C24921N0177 | Novartis Pharmaceuticals Corporation | $283.5k | 11/5/20 | 11/5/20 | 11/5/20 | |
Delivery Order 36F79720D0180-36C25025F0384 | Novartis Pharmaceuticals Corporation | $598.1k | 2/5/25 | 8/31/25 | 2/5/25 | |
Delivery Order 36F79720D0180-36C24525N0558 | Novartis Pharmaceuticals Corporation | $33.8k | 4/11/25 | 4/18/25 | 4/11/25 |